Improving patient outcomes for treatment-resistant schizophrenia
We support clinicians and health systems with expert guidance, implementation support, and education so patients receive timely, safe, and effective evidence-based TRS treatment locally from their own providers.
Clozapine is the only FDA-approved medication for treatment-resistant schizophrenia (TRS), yet it is significantly underused. In the post-REMS era, with simplified monitoring requirements and updated clinical guidelines, there are fewer barriers to clozapine access than ever before. TRS ACCESS—Advocacy, Clinical Consultation, Education, and Support Service—is building a network of clinicians and clinics ready to deliver timely, evidence-based TRS care. We help health systems and providers expand safe, effective use of clozapine and long-acting injectable antipsychotics, improving outcomes for people with TRS.
The TRS ACCESS Network is supported by the generous philanthropy of the CNR Foundation.
Abigail Donovan, MD explains our mission
Learn about the comprehensive approach behind TRS ACCESS and how we're helping clinicians become capable of prescribing clozapine and long-acting injectables safely and effectively for patients with treatment-resistant schizophrenia.
Clozapine is proven to be the most effective treatment for TRS, but many patients never receive it. The TRS ACCESS Network exists to close this gap by supporting earlier, safer, and more consistent use of clozapine and other best-practice interventions.
We partner with clinicians, clinics, and health systems to:
Abigail Donovan, MD explains the importance of patient outcomes
Understanding the critical importance of measuring and improving patient outcomes in treatment-resistant schizophrenia, and how evidence-based approaches can transform lives and healthcare delivery. Our focus on outcome-based care ensures that every intervention we support leads to measurable improvements in patient well-being and recovery.
Expert clinicians dedicated to TRS ACCESS services
Co-director, MGH Psychosis Clinical and Research Program
Oliver Freudenreich directs the TRS ACCESS program and leads our consultation service, providing expert guidance to clinicians managing complex cases and supporting clinicians to become capable of prescribing clozapine safely and effectively.
Director of Clinical Services, MGH Psychosis Clinical and Research Program
Abigail Donovan specializes in the early detection and treatment of schizophrenia in adolescents and adults, with a focus on outcome-based care and quality improvement initiatives.
Medical Director, MGH Clozapine Clinic
Carol Lim serves as the medical director of our Clozapine Clinic and leads educational initiatives to help other healthcare systems establish safe and effective clozapine monitoring programs.
Psychiatric Nurse Practitioner & LAI Specialist
Sarah Maclaurin provides expert clinical care and specializes in long-acting injectable antipsychotic medications, offering consultation and training to healthcare providers.
Clinical Psychologist & Implementation Specialist
Cheryl Foo leads implementation efforts to help clinicians and healthcare systems become capable of prescribing clozapine and long-acting injectables safely and effectively.
Program Coordinator
Marta Hernandez coordinates program activities and provides administrative support to ensure seamless patient care and program operations.
Program Manager
Leah Namey manages program operations and oversees quality improvement initiatives within the TRS ACCESS program.
Comprehensive support for evidence-based TRS care
Expert consultation for clinicians managing complex cases of difficult to treat psychosis, providing guidance on diagnosis, treatment planning, and clozapine initiation and management.
Oliver Freudenreich, MD on consultation services
We specialize in optimizing clozapine treatment, navigating today's regulatory landscape to ensure safe, effective prescribing. Our support includes protocol development, staff training, and education to uphold best practices in clozapine management.
Carol Lim, MD on clozapine clinic services
Training and consultation on long-acting injectable antipsychotic medications, helping clinicians optimize medication adherence and improve treatment outcomes.
Sarah Maclaurin, PMHNP-BC on LAI expertise
Implementation support to help healthcare systems and clinicians become capable of prescribing clozapine and long-acting injectable safely and effectively, including staff training, workflow development, and ongoing support.
Cheryl Foo, PhD on program implementation
Educational materials and publications from our faculty
Second Edition - A comprehensive guide to understanding and treating psychotic disorders in clinical practice.
A guide for patients and families dealing with serious mental illness.
Emergency Management - A comprehensive guide for managing substance use in psychiatric emergencies.
And Other Stories from the World of Emergency Psychiatry.
Oliver Freudenreich, MD discusses secondary psychosis and differential diagnosis considerations.
Abigail Donovan, MD explains the spectrum of schizophrenia, covering causes, symptoms, and treatment approaches.
Educational presentation on treatment-resistant schizophrenia and clozapine therapy approaches.
Research seminar discussing current clinical research initiatives in psychosis treatment and management.
Get in touch with our specialized team
151 Merrimac St, Suite 401
Boston, MA 02114
617-643-1175